Fierce Pharma

APRIL 17, 2023

In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off kdunleavy Mon, 04/17/2023 - 11:34

255

255

World of DTC Marketing

JANUARY 24, 2022

Most small biotech companies rely on venture capitalist funding to develop new drugs but is that a good way to go? VCs invest money in biotech because they see a potential windfall via a profitable acquisition or sale, but when the FDA weighs in with delays, VCs can be ruthless. not necessarily. Only about $2.2

FDA 225

FDA Marketing Medicine Government 225

World of DTC Marketing

MARCH 7, 2022

Biotech start-ups face challenges in raising money and cutting through the “noise” of other prominent pharma marketers, but their website can provide a wealth of insights into what visitors want to know. One of our most frequent requests is to analyze small biotech websites. Click-stream analysis can be critical.

Media 180

Media Marketing Recruitment Doctors 180

Zymewire

MAY 14, 2024

CEO Perspectives on funding clinical-stage biotech & pharma companies. An insightful discussion from accomplished biotech CEOs from COG New England 2024.

Pharma 52

Pharma 52

World of DTC Marketing

AUGUST 19, 2020

We need to ask why smaller biotech firms can develop so many new drugs while the bigger companies flounder. A lot of big pharma people are joining smaller biotech companies because of the promise of a huge payday. Laurie, a close friend of mine, left a good job with Pfizer to take a job with small biotech in Cambridge as a Director.

Pharma 217

Pharma Leads Management Marketing 217

PM360

DECEMBER 20, 2023

Earlier this year, EY reported that a significant proportion of biotechs were set to run out of funds within two years and the current outlook makes that a real concern to many in the industry. However, with many biotechs running out of road, the question is whether they can hang on for long enough for a deal to be done.

Biopharma 111

Biopharma Pharma Marketing Management 111

World of DTC Marketing

JANUARY 10, 2022

Pharma companies are flush with cash and looking to make deals, but there are still a lot of small biotech companies that don’t have enough money to launch their products entirely. For many of these small biotech companies, the restrictive costs are the launch costs. appeared first on World of DTC Marketing.com.

Food and Drug Administration 213

Food and Drug Administration Pharma Marketing Food 213

Fierce Pharma

SEPTEMBER 21, 2023

In this episode of "The Top Line," Annalee Armstrong and Gabrielle Masson shine a spotlight on some of the most promising companies in the biotech world. |

130

130

pharmaphorum

FEBRUARY 2, 2024

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T specialist Kyverna and private rounds for Eyconis, COUR Pharmaceuticals, Basking Biosciences, Enterprise Therapeutics, Halia Therapeutics and NeoPhore.

Pharmaceutical 90

Pharmaceutical 90

Fierce Pharma

AUGUST 10, 2023

A Fierce Biotech report examined Singapore's search for its big biotech success story. Astellas has won FDA approval for a geographic atrophy therapy that the company obtained from its acquisition of Iveric Bio. Astellas has won an FDA nod for a geographic atrophy therapy from its acquisition of Iveric Bio. And more.

FDA 130

FDA Pharma Manufacturing 130

pharmaphorum

JANUARY 24, 2024

CG Oncology completes the first biotech IPO of 2024, raising $380 million for its oncolytic virus bladder cancer immunotherapy.

131

131

Pharmaceutical Commerce

MARCH 6, 2024

In this Pharmaceutical Commerce video interview, Emma Banks, CEO of ramarketing, discusses how the balance between onshoring and outsourcing will evolve, how long will the current slowdown in biotech investment likely last, and what factors might influence its duration.

Pharmaceutical 105

Pharmaceutical 105

PharmaVoice

MAY 16, 2024

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

Pharmaceutical 52

Pharmaceutical 52

pharmaphorum

JANUARY 30, 2024

Legislation filed in the US is seeking to block Chinese biotech companies from federal contracts on the grounds they are a national security concern

109

109

European Pharmaceutical Review

MAY 23, 2023

New research by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20 percent of European biotech companies are now headquartered in Switzerland. Sixty three out of a total of 265 companies settling in Switzerland were biotechs. Why are European biotech’s choosing Switzerland?

Biopharma 109

Biopharma Government Pharma Medicine 109

pharmaphorum

FEBRUARY 27, 2024

UK biotech Curve Therapeutics raises $51 million in a Pfizer-led Series A that will support its platform for screening drugs within cells.

99

99

pharmaphorum

APRIL 10, 2024

e-therapeutics is the latest UK biotech to say it plans to delist from the AIM, citing a lack of interest from institutional investors.

92

92

PharmaTech

MAY 17, 2024

Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.

Pharma 52

Pharma 52

PM360

DECEMBER 20, 2023

How can biotech companies successfully raise funds in an environment where investment in the industry is headed for a third straight year of decline? listed on the stock exchanges, is up 13%, according to Leerink Partners’ “Navigating the Complex Terrain: Healthcare and Biotech Markets in Q3 2023” report.

Management 109

Management Marketing Healthcare Healthcare 109

pharmaphorum

MARCH 7, 2024

Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.

79

79

PharmaVoice

NOVEMBER 30, 2023

John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.

Marketing 111

Marketing 111

PharmaVoice

FEBRUARY 21, 2024

A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

75

75

pharmaphorum

FEBRUARY 15, 2024

Gene-editing biotech Prime Medicine has priced an initial public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge, Massachusetts-based company is offering 19.2 million shares at $6.25

Medicine 92

Medicine 92

Pharmaceutical Technology

MAY 17, 2024

Cannabidiol is under clinical development by Cannamore Biotechs and currently in Phase II for Ulcerative Colitis.

52

52

pharmaphorum

JANUARY 25, 2024

Our latest crop of biotech financings features rounds for Synnovation Therapeutics and Adicet Bio, Calluna Pharma, Accent Therapeutics, GenEdit and IMU Bio

Pharma 81

Pharma 81

pharmaphorum

JANUARY 18, 2024

BridgeBioPharma raises $1.25bn to support acoramidis rollout and trials, plus other biotech financings for Tr1X, Comanche, Ratio, and Myrobalan

85

85

MedCity News

JULY 14, 2023

Inflammation and immunology biotech Apogee Therapeutics and Sagimet Biosciences, a company developing a drug for the fatty liver disease NASH, are the latest biotech companies to join the public markets. Both companies upsized their IPOs, raising cash for clinical trials.

Marketing 91

Marketing Biopharma Pharma 91

Fierce Pharma

APRIL 29, 2024

The price tag includes both the approved cancer drug Qinlock and another Deciphera candidate heading to the FDA’s desk in the coming months.

321

321

MedCity News

JANUARY 20, 2023

Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.

Pharmaceutical 123

Pharmaceutical Biopharma Pharma 123

Pharmaceutical Technology

JULY 6, 2022

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7.

Marketing 129

Marketing Biopharma Pharma Retail 129

PharmExec

JULY 12, 2023

Recent data and commentary offer insights into how biologics vs. small molecule patent protections under the Inflation Reduction Act pricing scenarios is impacting investing in the biotech sector.

98

98

MedCity News

DECEMBER 27, 2023

While it may appear that hospital administrators and biotech CEOs have quite dissimilar jobs because they face different challenges daily, this article attempts to conveys the value of some of the underlying principles that one can develop in the field of hospital administration, that may have some value in other healthcare fields and in other executive (..)

Healthcare 96

Healthcare Healthcare Biopharma Patients 96

pharmaphorum

JANUARY 25, 2024

UK biotech shows "resilience" in 2023, raising £1.8bn despite lacklustre global financing market, says BIA

Marketing 92

Marketing 92

MedCity News

NOVEMBER 13, 2023

Novartis gains global rights to Legend Biotech cell therapies that address DLL3, a promising target for lung cancers and other types of solid tumors. The pharmaceutical giant may make these therapies using T-Charge, its next-generation CAR T-cell therapy manufacturing technology.

Manufacturing 101

Manufacturing Pharmaceutical Biopharma Pharma 101

PharmaVoice

MARCH 13, 2024

Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.

69

69

Pharmaceutical Technology

MAY 2, 2024

As the obesity space becomes more congested, clinical trial recruitment has become a larger issue for small biotechs.

Recruitment 59

Recruitment Patients 59

PharmaVoice

APRIL 30, 2024

From resurrecting an extinct species to improving regenerative medicines with plant-based materials, these biotechs are on the leading edge of science.

Medicine 52

Medicine Leads 52